Aldactone 25mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

aldactone 25mg tablet blister pack

pfizer australia pty ltd - spironolactone, quantity: 25 mg - tablet, film coated - excipient ingredients: macrogol 400; hypromellose; maize starch; calcium sulfate dihydrate; magnesium stearate; povidone; flavour; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. alda

METHOBLASTIN methotrexate 2.5mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

methoblastin methotrexate 2.5mg tablet bottle

pfizer australia pty ltd - methotrexate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; lactose monohydrate; polysorbate 80; microcrystalline cellulose; pregelatinised maize starch - antineoplastic chemotherapy: treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatolo

SPIRACTIN 100 spironolactone 100mg tablets Australia - English - Department of Health (Therapeutic Goods Administration)

spiractin 100 spironolactone 100mg tablets

alphapharm pty ltd - spironolactone, quantity: 100 mg - tablet, uncoated - excipient ingredients: sunset yellow fcf aluminium lake; maize starch; povidone; magnesium stearate; peppermint oil; sodium starch glycollate; purified talc; erythrosine aluminium lake; polysorbate 80; quinoline yellow aluminium lake; lactose monohydrate; microcrystalline cellulose - essential hypertension. spironolactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. spironolactone improves the hypotensive action of thiazide diuretics, while at the same time reducing or preventing potassium loss due to the thiazide. spironolactone enhances the effectiveness of other antihypertensive agents such as beta-blockers, vasodilators, etc. as adjunctive therapy in malignant hypertension. in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate. prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate. congestive cardiac failure. when used alone, spironolactone is effective in the management of oedema and sodium retention associated with congestive cardiac failure. spironolactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics

SPIRACTIN 25 spironolactone 25mg tablets Australia - English - Department of Health (Therapeutic Goods Administration)

spiractin 25 spironolactone 25mg tablets

alphapharm pty ltd - spironolactone, quantity: 25 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; peppermint oil; purified talc; sodium starch glycollate; lactose monohydrate; povidone; microcrystalline cellulose; magnesium stearate; polysorbate 80; sunset yellow fcf aluminium lake; erythrosine aluminium lake; maize starch - essential hypertension. spironolactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. spironolactone improves the hypotensive action of thiazide diuretics, while at the same time reducing or preventing potassium loss due to the thiazide. spironolactone enhances the effectiveness of other antihypertensive agents such as beta-blockers, vasodilators, etc. as adjunctive therapy in malignant hypertension. in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate. prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate. congestive cardiac failure. when used alone, spironolactone is effective in the management of oedema and sodium retention associated with congestive cardiac failure. spironolactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics

METHOBLASTIN methotrexate 10mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

methoblastin methotrexate 10mg tablet bottle

pfizer australia pty ltd - methotrexate, quantity: 10 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; maize starch; polysorbate 80; microcrystalline cellulose; magnesium stearate - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. psoriasis chemotherapy: (see warnings box and precautions). because of the high risk attending to its use, methoblastin is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultations. rheumatoid

NEFAZODONE HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

nefazodone hydrochloride tablet

ranbaxy pharmaceuticals inc. - nefazodone hydrochloride (unii: 27x63j94gr) (nefazodone - unii:59h4fcv1tf) - tablet - 50 mg - nefazodone hydrochloride tablets, usp is indicated for the treatment of depression. when deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride tablets, usp treatment (see warnings ). in many cases, this would lead to the conclusion that other drugs should be tried first. the efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the dsm-iii or dsm-iiir category of major depressive disorder (see clinical pharmacology ). a major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). it must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed

APO-NORFLOXACIN norfloxacin 400 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

apo-norfloxacin norfloxacin 400 mg tablet bottle

arrow pharma pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - the treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. the treatment of adults with gastrointestional infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infections.

ROXIN norfloxacin 400 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

roxin norfloxacin 400 mg tablet bottle

arrow pharma pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note. specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infection.

JINARC TABLET 45MG15MG Singapore - English - HSA (Health Sciences Authority)

jinarc tablet 45mg15mg

otsuka pharmaceuticals (singapore) pte. ltd. - (15mg tablet) tolvaptan; (45mg tablet) tolvaptan - tablet - (15mg tablet) tolvaptan 15.000mg; (45mg tablet) tolvaptan 45.0mg

JINARC TABLET 60MG30MG Singapore - English - HSA (Health Sciences Authority)

jinarc tablet 60mg30mg

otsuka pharmaceuticals (singapore) pte. ltd. - (30mg tablet) tolvaptan; (60mg tablet) tolvaptan - tablet - (30mg tablet) tolvaptan 30.000mg; (60mg tablet) tolvaptan 60.000mg